Novel antiarthritic agents with 1,2-isothiazolidine-1-,1-dioxide (γ- sultam) skeleton: Cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase

Journal of Medicinal Chemistry

Volumn 43, Issue 10, 2000, Pages 2040-2048

  Inagaki, Masanao ^a   Tsuri, Tatsuo ^a   Jyoyama, Hirokuni ^a   Ono, Takashi ^a   Yamada, Katsutoshi ^a   Kobayashi, Mika ^a   Hori, Yozo ^a   Arimura, Akinori ^a   Yasui, Kiyoshi ^a   Ohno, Kouji ^a   Kakudo, Shinji ^a   Koizumi, Kenzo ^a   Suzuki, Ryuji ^a   Kato, Miyako ^b   Kawai, Shinichi ^b   Matsumoto, Saichi ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3,5 DI TERT BUTYL 4 HYDROXYBENZYLIDENE) 1 METHOXY 2 PYRROLIDINONE; 4 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL) 2 METHYL 1,2 OXAZIN 3 ONE; ANTIRHEUMATIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; INTERLEUKIN 1; LIPOXYGENASE INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; S 2474; SATIGREL; THIAZOLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; IMMUNOMODULATION; NONHUMAN; PROSTAGLANDIN SYNTHESIS; RAT; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONATE 5-LIPOXYGENASE; ARTHRITIS; ARTHRITIS, EXPERIMENTAL; BLOOD PLATELETS; CYCLIC S-OXIDES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; EDEMA; FEMALE; GASTRIC MUCOSA; HUMANS; INTERLEUKIN-1; ISOENZYMES; LEUKOTRIENE B4; LIPOXYGENASE INHIBITORS; MALE; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, INBRED LEW; STRUCTURE-ACTIVITY RELATIONSHIP; SYNOVIAL MEMBRANE; THIAZOLES;

EID: 0034075728     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9906015     Document Type: Article

References (51)

1. Vane, J. R.; Botting, R. M. Antiinflammatory Drugs and Their Mechanism of Action. Inflammation Res. 1998, 47 (Suppl. 2), S78-S87.
2. (a) Kimmey, M. B. NSAIDS, Ulcers, and Prostaglandins. J. Rheumatol. 1992, 19, 68-73.
3. (b) Peskar, B. M. On the Synthesis of Prostaglandins by Human Gastric Mucosa and its Modification by Drugs. Biochim. Biophys. Acta. 1977, 487, 307-314.
4. Miller, T. A. Protective Effects of Prostaglandins against Gastric Mucosal Damage: Current Knowledge and Proposed Mechanisms. Am. J. Physiol. 1983, 245, G601-G623.
5. (a) Xie, W.; Chipman, J. G.; Robertson, D. L.; Erikson, R. L.; Simmons, D. L. Expression of a Mitogen-Responsive Gene Encoding Prostaglandin Synthase is Regulated by mRNA Splicing. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 2692-2696.
6. (b) Kujubu, D. A.; Fletcher, B. S.; Varnum, B. C.; Lim, R. W.; Herschman, H. R. TIS 10, a Phorbol Ester Tumor Promoter-inducible mRNA from Swiss 3T3 cells, Encodes a Novel Prostaglandin Synthase/Cyclooxygenase Homologue. J. Biol. Chem. 1991, 266, 12866-12872.
7. (c) Hla, T.; Neilson, K. Human Cyclooxygenase-2 c-DNA. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 7384-7388.
8. (d) Seibert, K.; Zhang, Y.; Leathy, K.; Hauser, S.; Masferrer, J.; Perkins, W.; Lee, L.; Isakson, P. Pharmacological and Biochemical Demonstration of the Role of Cyclooxygenase 2 in Inflammation and Pain. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 12013-12017.
9. Masferrer, J. L.; Zweifel, B. S.; Manning, P. T.; Hauser, S. D.; Leathy, K. M.; Smith, W. G.; Isakson, P. C.; Seibert, K. Selective Inhibition of Inducible Cyclooxygenase 2 In Vivo is Antiinflammatory and Nonulcerogenic. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3228-3232.
10. Hidaka, T.; Hosoe, K.; Ariki, Y.; Takeo, K.; Yamashita, T.; Katsumi, I.; Kondo, H.; Yamashita, K.; Watanabe, K. Pharmacological Properties of a New Antiinflammatory Compound, α-(3,5-Di-tert-butyl-4-hydroxybenzylidene)-γ-butyrolactone (KME-4), and its Inhibitory Effects on Prostaglandin Synthetase and 5-Lipoxygenase. Jpn. J. Pharmacol. 1984, 36, 77-85.
11. Ikuta, H.; Shirota, H.; Kobayashi, S.; Yamagishi, Y.; Yamada, K.; Yamatsu, I.; Katayama, K. Synthesis and Antiinflammatory Activities of 3-(3,5-Di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones. J. Med. Chem. 1987, 30, 1995-1998.
12. Wong, S.; Lee, S. J.; Frierson, M. R., III; Proch, J.; Miskowski, T. A.; Rigby, B. S.; Schmolka, S. J.; Naismith, R. W.; Kreutzer, D. C.; Lindquist, R Antiarthritic Profile of BF-389 - A Novel Antiinflammatory Agent with Low Ulcerogenic Liability. Agents Actions 1992, 37, 90-98.
13. Unangst, P. C.; Connor, D. T.; Cetenko, W. A.; Sorenson, R. J.; Kostlan, C. R.; Sircar, J. C.; Wright, C. D.; Schrier, D. J.; Dyer, R. D. Synthesis and Biological Evaluation of 5-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]oxazoles, -thiazoles, and -imidazoles: Novel Dual 5-Lipoxygenase and Cyclooxygenase Inhibitors with Antiinflammatory Activity. J. Med. Chem. 1994, 37, 322-328.
14. (a) Brain, S. D.; Williams, T. J. Leukotrienes and Inflammation. Pharmacol. Ther. 1990, 46, 57-66.
15. (b) Vaananen, P. M.; Keenan, C. M.; Grisham, M. B.; Wallace, J. L. Pharmacological Investigation of the Role of Leukotrienes in the Pathogenesis of Experimental NSAID Gastropathy. Inflammation 1992, 16, 227-240.
16. (c) Guslandi, M. Gastric Effects of Leukotrienes. Prostaglandins, Leukotrienes Med. 1987, 26, 203-208.
17. (d) Asako, H.; Kubes, P.; Wallace, J.; Gaginella, T.; Wolf, R. E.; Granger, D. N. Indomethacin-Induced Leukocyte Adhesion in Mesenteric Venules: Role of Lipoxygenase Products. Am. J. Physiol. 1992, 262, G903-G908.
18. Bondeson, J. The Mechanisms of Action of Diseese-Modifying Antirheumatic Drugs: A Review with Emphasis on Macrophage Signal Transduction and the Induction of Proinflammatory Cytokines. Gen. Pharmacol. 1997, 29, 127-150.
19. (a) Bleedverd, F. Tenidap: A Novel Cytokine-Modulating Antirheumatic Drug for the Treatment of Rheumatoid Arthritis. Scand. J. Rheumatol. 1994, 23, 31-44.
20. (b) Madhok, K. Tenidap. Lancet 1995, 346, 481-485.
21. (c) Bondeson, J. Effects of Tenidap on Intracellular Signal Transduction and the Induction of Proinflammatory Cytokines: A Review Gen. Pharmacol. 1996, 27, 943-956.
22. (a) Marketletter Oct. 17, 1996.
23. (b) Marketletter Feb. 02, 1998.
24. (a) Ku, G.; Doherty, N. S.; Wolos, J. A.; Jackson, R. L. Inhibition by Probucol of Interleukin 1 secretion and its Implication in Atherosclerosis. Am. J. Cardiol. 1988, 62, 77B-81B.
25. (b) Akeson, A. L.; Woods, C. W.; Mosher, L. B.; Thomas, C. E.; Jackson, R. L. Inhibition of IL-1β Expression in THP-1 Cells by Probucol and tocopherol. Atherosclerosis 1991, 86, 261-270.
26. (c) Woolaghan, E.; Li, S.-R.; Forster, L.; Änggard, E. E.; Ferns, G. A. A. Probucol Inhibits IL-1β Synthesis by Minimally Modified LDL-Stimulated Human Mononuclear Cells. Clin. Sci. 1995, 88, 4-5.
27. Erman, W. F.; Kretschmar, H. C. Syntheses and Facile Cleavage of Five-Membered Ring Sultams. J. Org. Chem. 1961, 26, 4841-4850.
28. 2 of Z-isomers. Vinyl protons of Z-isomers shifted higher than those of the corresponding E-isomers in NMR study.
29. X-ray crystallographic data of 10b and 12b are given in the Supporting Information.
30. (a) Mindl, J.; Šterna, V. Kinetics and Mechanism of Hydrolysis of Aryl N-Methoxycarbamates and Their Derivatives. Coll. Czech. Chem. Commun. 1983, 48, 900-905.
31. (b) Oesper, R. E.; Broker, W. Some New Hydroxy-Urethanes and Chromo-Isomeric Silver Salts of Their Acyl Derivatives. III. J. Am. Chem. Soc. 1925, 47, 2606-2608.
32. (c) Steinberg, G. M.; Bolger, J. N-Hydrox'y Aryl Carbamates. A Class of Hydroxamic Acids Which Form Stable Phosphorylated and Sulfated Derivatives. J. Org. Chem. 1956, 21, 660-662.
33. (a) Wolfgang, K. Chloroalkanesulfonyl Chloride. Chem. Abstr. 1969, 71, 101310x.
34. (b) Ger. Patent Application 1300933, 1969.
35. Shirota, H.; Kobayashi, S.; Terao, K.; Sakuma, Y.; Yamada, K.; Ikuta, H.; Yamagishi, Y.; Yamatsu, I.; Katayama, K. Effect of the Novel Non-Steroidal Antiinflammatory Agent N-Methoxy-3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-one on In Vitro Generation of Some Inflammatory Mediators. Arzneim.-Forsch. / Drug. Res. 1987, 37, 936-940.
36. 4 Formation by Azelastine in Rat Mixed Peritoneal Cells. Int. Arch. Allergy Appl. Immunol. 1990, 92, 143-147.
37. Auwerx, J. The Human Leukemia Cell Line, THP-1: A Multifacetted Model for the Study of Monocyte-Macrophage Differentiation. Experientia 1991, 47, 22-30.
38. (a) Winter, C. A.; Rilsey, E. A.; Nuss, G. W. Carrageenin-Induced Edema in Hind Paw of the Rat as an Assay for Antiinflammatory Drugs. (27849) Proc. Soc. Exp. Biol. Med. 1962, 111, 544-547.
39. (b) Shirota, H.; Chiba, K.; Ono, H.; Yamamoto, H.; Kobayashi, S.; Terao, K.; Ikuta, H.; Yamatsu, I.; Katayama, K. Pharmacological Properties of the Novel Non-Steroidal Antiinflammatory Agent N-Methoxy-3-(3,5-di-tert-butyl-4-hydroxybenzylidene)-pyrrolidin-2-one. Arzneim.-Forsch. / Drug. Res. 1987, 37, 930-936.
40. (a) Winder, C. V.; Lembke, L. A.; Stephens, M. D. Comparative Bioassay of Drugs in Adjuvant-Induced Arthritis in Rats: Flufenamic Acid, Mefenamic Acid, and Phenylbutazone. Arthritis Rheum. 1969, 12, 472-482.
41. (b) Walz, D. T.; Dimartino, M. J.; Kuch, J. H.; Zuccarello, W. Adjuvant-Induced Arthritis in Rats I. Temporal Relationship of Physiological, Biochemical, and hemotological Parameters (35392). Proc. Soc. Exp. Biol. Med. 1971, 136, 907-910.
42. Kawai, S.; Nishida, S.; Kato, M.; Furumaya, Y.; Okamoto, R.; Koshino, T.; Mizushima, Y. Comparison of Cyclooxygenase-1 and -2 Inhibitory Activities of Various Nonsteroidal Antiinflammatory Drugs Using Human Platelets and Synovial Cells. Eur. J. Pharmacol. 1998, 347, 87-94.
43. Futaki, N.; Takahashi, S.; Kitagawa, T.; Yamakawa, Y.; Yanaka, M.; Higuchi, S. Selective Inhibition of Cyclooxygenase-2 by NS-398 in Endotoxin Shock Rats In Vivo. Inflammation Res. 1997, 46, 496-502.
44. Neither 12b nor 10b could be detected in the plasma after oral administration of 12b. Furthermore, orally active 10b could not be detected in the plasma after intravanous injection of 12b to nonfasted rats at a dose of 1 mg/kg. Compound 12b could not be thought to isomerize under the conditions of this assay. However, 12b was irreversibly isomerized slowly to 10b in the MeOH solution at room temperature.
45. Futaki, N.; Takahashi, S.; Yokoyama, M.; Arai, I.; Higuchi, S.; Otomo, S. NS 398, a New Antiinflammatory Agent, Selectively Inhibits Prostaglandin G/H Synthase/Cyclooxygenase (COX-2) Activity In Vitro. Prostaglandins 1994, 47, 55-59.
46. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J. Med. Chem. 1997, 40, 1347-1365.
47. Minkes, M.; Stanford, N.; Chi, M. M-Y.; Roth, G. J.; Raz, A.; Needleman, P.; Majerus, P. W. Cyclic Adenosine 3′, 5′-Monophosphate Inhibits the Availability of Arachidonate to Prostaglandin Synthetase in Human Platelet Suspensions. J. Clin. Invest. 1977, 59, 449-454.
48. (a) Dayer, J.-M.; Krane, S. M.; Russell, R. G. G.; Robinson, D. R. Production of Collagenase and Prostaglandins by Isolated Adherent Rheumatoid Synovial Cells. Proc. Natl. Acad. Sci. U.S.A. 1976, 73, 945-949.
49. 2 Production Following its Intracellular Conversion into Cyclooxygenase Inhibitors. Eur. J. Pharmacol. 1997, 329, 181-187.
50. Japanese Patent Application 209564, 1985.
51. Japanese Patent Application 268, 1990.